NCT06079398 - A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Achondroplasia

Interventions

DRUG

Navepegritide

Once-weekly subcutaneous injection of 100 µg/kg Navepegritide

DRUG

Placebo for Navepegritide

Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide

Trial Locations (16)

1023

RECRUITING

Ascendis Investigational Site, Auckland

2100

RECRUITING

Ascendis Investigational Site, Copenhagen

3052

RECRUITING

Ascendis Investigational Site, Parkville

4020

RECRUITING

Ascendis Investigational Site, Linz

13353

RECRUITING

Ascendis Investigational Site, Berlin

17176

RECRUITING

Ascendis Investigational Site, Stockholm

20132

RECRUITING

Ascendis Investigational Site, Milan

53705

RECRUITING

Ascendis Investigational Site, Madison

55102

RECRUITING

Ascendis Investigational Site, Saint Paul

75743

RECRUITING

Ascendis Investigational Site, Paris

77030

RECRUITING

Ascendis Investigational Site, Houston

00029

RECRUITING

Ascendis Investigational Site, Helsinki

D01 YC76

RECRUITING

Ascendis Investigational Site, Dublin

0372

RECRUITING

Ascendis Investigational Site, Oslo

3000-602

RECRUITING

Ascendis Investigational Site, Coimbra

SE1 7EH

RECRUITING

Ascendis Investigational Site, London